DPYSL3 and prostate carcinoma: To assess whether the CRMP4 promoter methylation status would be useful for prognosis or diagnosis of metastasis in prostate cancer patients, prostate cancer specimens obtained via radical prostatectomy from 203 patients (Supplementary Table S2) were evaluated for their CRMP4 promoter methylation status using a methylation-specific PCR (MSP) method.